Nootropic / Neuroprotective

Semax

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in Russia as a nootropic and neuroprotective agent. It is among the most researched peptide nootropics, with clinical use in Russia for stroke recovery, cognitive decline, and attention disorders.

What is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a metabolically stable analogue of the ACTH(4-7) fragment. The ACTH(4-10) fragment was known to have cognitive-enhancing effects but was rapidly degraded in the body; Semax was designed to extend its half-life through structural modifications.

Semax is approved in Russia as a pharmaceutical drug for cerebrovascular disease, stroke, and cognitive impairment, administered intranasally. Outside of Russia and Ukraine (where it also holds approval), it is classified as a research compound. A modified version, N-Acetyl Semax, is also available in research markets and is believed to have enhanced stability.

Mechanism of Action

Semax acts through several complementary mechanisms that collectively support cognitive function and neuroprotection:

BDNF & NGF Upregulation

Semax robustly increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and other brain regions. BDNF is critical for synaptic plasticity, long-term potentiation (LTP), and neurogenesis — the cellular underpinnings of learning and memory. This is considered Semax's primary mechanism for cognitive enhancement.

Dopaminergic & Serotonergic Modulation

Research indicates Semax increases dopamine and serotonin turnover in the brain, which may contribute to improvements in motivation, focus, and mood observed in both animal models and human subjects.

Neuroprotection

In stroke models, Semax significantly reduces infarct size and improves neurological outcomes when administered shortly after ischemic events. Mechanisms appear to include anti-inflammatory effects, reduced oxidative stress, and preservation of mitochondrial function in neurons.

Melanocortin Receptor Activity

As an ACTH analogue, Semax interacts with melanocortin receptors (MC4R, MC5R) in the brain, contributing to attentional and arousal-related effects independent of the HPA axis (it does not stimulate cortisol release in the same way as full-length ACTH).

Research Overview

Semax has a broader clinical research record than many peptide nootropics, though the bulk of this research comes from Russian institutions. Independent Western replication is limited.

Stroke & ischemia: Multiple Russian clinical trials demonstrate Semax reduces neurological deficit and improves recovery outcomes in ischemic stroke when administered intranasally within the first hours to days post-event. This is the indication for which clinical evidence is strongest.
Cognitive enhancement: Studies in healthy volunteers and patients with cognitive impairment report improvements in attention, memory, and processing speed. Effect sizes and methodology vary across studies.
ADHD: Preliminary Russian research examined Semax in attention deficit disorders with encouraging results, but no rigorous double-blind RCTs comparable to Western ADHD drug trials exist.
Optic nerve disease: Some research explored Semax in glaucoma and optic neuritis, with animal models showing neuroprotective effects on retinal ganglion cells.

Potential Benefits

Based on available research. Not medical claims.

Cognitive enhancement — attention, working memory, and processing speed
Neuroprotective effects, particularly relevant after ischemic events
Increased BDNF expression supporting neuroplasticity
Potential support for recovery from brain injury or stroke
Mood stabilization and increased motivation in some reports
May improve focus and reduce cognitive fatigue

Safety Profile

Semax has a relatively well-characterized safety profile given its clinical use in Russia since the 1980s and 1990s. Key considerations for researchers include:

Generally well-tolerated in clinical data; most reported side effects are mild and transient (nasal irritation with intranasal use, mild anxiety or over-stimulation at higher doses).
Stimulating effects may disrupt sleep if taken late in the day — most protocols recommend morning administration.
No physical dependence has been reported in clinical literature, but subjective reports of tolerance at consistent doses exist in user communities.
Long-term effects on the dopaminergic system from chronic use are not established in clinical data.
The research evidence base is predominantly from Russian sources, limiting independent verification of safety claims.
Drug interactions with psychiatric medications, stimulants, or nootropic stacks are not characterized in the literature.

Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. We are not medical professionals. All compounds discussed are intended for research purposes only. Always consult with a qualified healthcare professional before making any decisions about peptides or supplements. Individual results may vary. See our full disclaimer.

Affiliate Disclosure: This page contains affiliate links. We only recommend vendors we have personally vetted for COA compliance. We may earn a commission at no extra cost to you.